| 纯度 | > 85 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | CA11 |
| Uniprot No | O75493 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-328aa |
| 氨基酸序列 | HIGPAPD PEDWWSYKDN LQGNFVPGPP FWGLVNAAWS LCAVGKRQSP VDVELKRVLY DPFLPPLRLS TGGEKLRGTL YNTGRHVSFL PAPRPVVNVS GGPLLYSHRL SELRLLFGAR DGAGSEHQIN HQGFSAEVQL IHFNQELYGN FSAASRGPNG LAILSLFVNV ASTSNPFLSR LLNRDTITRI SYKNDAYFLQ DLSLELLFPE SFGFITYQGS LSTPPCSETV TWILIDRALN ITSLQMHSLR LLSQNPPSQI FQSLSGNSRP LQPLAHRALR GNRDPRHPER RCRGPNYRLH VDGVPHGR |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是假设性的示例参考文献，供参考。请注意这些文献可能并非真实存在，建议通过学术数据库进一步验证：
1. **文献名称**: "Cloning and Functional Characterization of Recombinant CA11 in Human Renal Cells"
**作者**: Smith A, et al.
**摘要**: 研究报道了人源CA11基因的克隆及其在HEK293细胞中的重组表达，证实其碳酸酐酶活性，并分析其在肾脏酸碱平衡中的潜在作用。
2. **文献名称**: "Structural Insights into CA11 by Recombinant Protein Crystallography"
**作者**: Tanaka K, et al.
**摘要**: 通过大肠杆菌表达系统纯化CA11重组蛋白，解析其晶体结构，揭示了其活性位点特征，为靶向药物设计提供结构基础。
3. **文献名称**: "CA11 Recombinant Protein as a Biomarker in Glioblastoma"
**作者**: Lee H, et al.
**摘要**: 利用哺乳动物细胞表达重组CA11蛋白，发现其在胶质瘤细胞中高表达，可能作为肿瘤微环境酸化的治疗靶点。
4. **文献名称**: "Enzymatic Activity of Recombinant CA11 in Tumor Progression"
**作者**: Gupta R, Supuran CT
**摘要**: 研究比较了CA11与其他碳酸酐酶同工酶的活性，发现其重组蛋白在低pH下催化效率显著，提示其在癌症转移中的调控作用。
**注意**：以上文献为示例，实际研究中请通过PubMed、Google Scholar等平台检索真实文献。若需具体文献，请提供更详细信息(如基因全称或研究背景)。
CA11 (Carbonic Anhydrase XI), a member of the carbonic anhydrase (CA) enzyme family, plays a critical role in pH regulation and CO₂ hydration. This zinc-containing metalloenzyme is primarily expressed in the cytoplasm and is involved in diverse physiological processes, including ion transport, metabolic homeostasis, and tissue-specific functions. Dysregulation of CA11 has been linked to pathologies such as cancer, neurological disorders, and metabolic syndromes, making it a potential therapeutic target or biomarker.
Recombinant CA11 protein is engineered through heterologous expression systems (e.g., *E. coli*, mammalian cells) to produce purified, functional enzymes for research and clinical applications. Its recombinant form retains catalytic activity, enabling studies on enzyme kinetics, inhibitor screening, and structural analysis. Researchers utilize it to explore CA11's role in tumor microenvironments, where altered pH influences metastasis and drug resistance. Additionally, it aids in developing isoform-specific inhibitors to minimize off-target effects seen with broad-spectrum CA inhibitors.
The production of recombinant CA11 often involves affinity tags (e.g., His-tag) for simplified purification, followed by biophysical validation (SDS-PAGE, Western blot) and activity assays. Its applications span drug discovery, diagnostic tool development, and mechanistic studies of CA-related diseases. As a research tool, recombinant CA11 bridges gaps in understanding CA isoform specificity and supports translational efforts to design precision therapies. Continued interest in CA11 underscores its biological relevance and therapeutic potential in modulating pH-dependent disease pathways.
×
